Please wait a moment . . .
In early 2020, as the COVID-19 pandemic reshaped our world, Medialis Ltd recognised the urgent need for a disease-specific quality of life (QoL) instrument for long COVID patients. This, led to the development of the PAC-19QoL. Rapid Development Timeline: We received ethical approval in October 2020 and initiated the development of the PAC-19QoL on November...
Medialis Ltd is proud to present our latest publication: “Real-world service cost’s for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis” in Current Medical Research & Opinions Real-world Evidence section Key Highlights: Innovative Use of Neutral Theory & Jandhyala Method: We leveraged these advanced methodologies to develop the nAMD Service Non-Drug...
Payors are crucial in the adoption of new medicines, especially in markets that prioritise cost-effectiveness. While HTA agencies and payors often prioritise clinical trial data, there are significant evidence gaps that these trials do not cover. Real-World Evidence (RWE) becomes crucial in this scenario, offering additional context and data to support reimbursement applications. Submitting incomplete...
In our pursuit of cost-effectiveness, are we overlooking a crucial factor? Our recent publication, “Real-world service costs for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis,” featured in Current Medical Research and Opinion, highlights significant strain costs affecting nAMD clinics, often ignored in traditional cost-effectiveness analyses. In our scenario analysis, while...
In today’s rapidly evolving healthcare landscape, how confident are you that your organisation is generating comprehensive and accurate evidence? At Medialis Ltd, we specialise in providing robust real-world evidence that empowers decision-making and drives better outcomes by enabling more patients to receive new medicines sooner. Medialis Ltd can help you develop Quality of Life...